Discrepancy in the Location of Prostate Cancer Indicated on Biparametric Magnetic Resonance Imaging and Pathologically Diagnosed Using Surgical Specimens

Author:

Tomioka Masayuki1,Nakane Keita1,Kawase Makoto1ORCID,Iinuma Koji1,Kato Daiki1,Kawase Kota1ORCID,Taniguchi Tomoki1ORCID,Tobisawa Yuki1,Sugino Fumiya2,Kaga Tetsuro3,Kato Hiroki3ORCID,Matsuo Masayuki3,Kito Yusuke4,Saigo Chiemi4,Suzui Natsuko5ORCID,Ito Takayasu6,Miyazaki Tatsuhiko5,Takeuchi Tamotsu4,Koie Takuya1ORCID

Affiliation:

1. Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan

2. Department of Urology, Gifu Municipal Hospital, Gifu 5008513, Japan

3. Department of Radiology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan

4. Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu 5011194, Japan

5. Department of Pathology, Gifu University Hospital, Gifu 5011194, Japan

6. Center for Clinical Training and Career Development, Gifu University Graduate School of Medicine, Gifu 5011194, Japan

Abstract

Accurate diagnosis of the localization of prostate cancer (PCa) on magnetic resonance imaging (MRI) remains a challenge. We aimed to assess discrepancy between the location of PCa pathologically diagnosed using surgical specimens and lesions indicated as possible PCa by the Prostate Imaging Reporting and Data System on MRI. The primary endpoint was the concordance rate between the site of probable clinically significant PCa (csPCa) identified using biparametric MRI (bpMRI) and location of PCa in the surgical specimen obtained using robot-assisted total prostatectomy. Among 85 lesions identified in 30 patients; 42 (49.4%) were identified as possible PCa on MRI. The 85 PCa lesions were divided into positive and negative groups based on the bpMRI results. None of the patients had missed csPCa. Although the diagnostic accuracy of bpMRI was relatively high for PCas located in the middle of the prostate (p = 0.029), it was relatively low for PCa located at the base of the prostate, all of which were csPCas. Although current modalities can accurately diagnose PCa, the possibility that PCa is present with multiple lesions in the prostate should be considered, even if MRI does not detect PCa.

Publisher

MDPI AG

Reference36 articles.

1. Underlying Features of Prostate Cancer-Statistics, Risk Factors, and Emerging Methods for Its Diagnosis;Berenguer;Curr. Oncol.,2023

2. Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis;Ilic;BMJ,2018

3. PI-RADS version 2.1: One small step for prostate MRI;Barrett;Clin. Radiol.,2019

4. NCCN Guidelines Updates: Management of Prostate Cancer;Mohler;J. Natl. Compr. Cancer Netw.,2019

5. (2024, February 27). Prostate Cancer (2022) NCCN Guidelines®. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3